Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab Together With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma

Trial Profile

A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab Together With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 2018 to 1 jan 2019.
    • 14 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 18 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top